Merck (MRK) Revenue & Earnings History | Quarter Chart
Income Statement▲
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Cash Flow Statement▲
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Balance Sheet▲
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Key Metrics▼
Merck (MRK) quarterly earnings & revenue
Merck (MRK) is the #38 largest public company in the world by market capitalization, operating in the Drug Manufacturers - General industry.
Merck (MRK) reported revenue of $16.61B for Q2 2026, up 5.1% year-over-year, with net income of $-1.33B and diluted EPS of $-0.54.
Over the last four reported quarters, Merck generated $66.40B in revenue and $3.17B in net income.
Merck's next earnings report is scheduled for October 29, 2026 before market open (provider scheduled date). Check the earnings calendar to see all companies reporting this week.
Merck quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q2 2026 | $16.61B | +5.1% | $-1.33B | $-0.54 |
| Q1 2026 | $16.29B | +4.3% | $-4.24B | $-1.72 |
| Q4 2025 | $16.32B | +4.5% | $2.96B | $1.19 |
| Q3 2025 | $17.18B | +3.2% | $5.79B | $2.32 |
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Novartis (NVS)